Skip to main content
NCBI home page
Springer logoLink to Springer
. 2023 May 1;130(11):1443–1449. doi: 10.1007/s00702-023-02640-7

Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease

P Tall 1,2,✉,#, M A Qamar 1,2,✉,#, L Batzu 1,2, V Leta 1,2, C Falup-Pecurariu 3,4, K Ray Chaudhuri 1,2
PMCID: PMC10645607  PMID: 37126118

Abstract

Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson’s disease (PD). CDD aims to mimic the physiological tonic dopamine release from striatal dopaminergic neurons and thus reduces the severity and duration of motor and non-motor fluctuations partly related to pulsatile levodopa stimulation. Non-motor symptoms and fluctuations are ubiquitous in PD and include sleep dysfunction, a problem that occurs in over 90% of PD patients across all stages, from prodromal to palliative. In this review, we discuss the currently available and in development non-oral dopaminergic CDD strategies with a focus on their efficacy in the treatment of the burdensome sleep dysfunction in PD.

Keywords: Continous drug delivery, Parkinsons, Levodopa, Apomorphine, LCIG, LECIGON, Sleep, Park-sleep

Introduction

Parkinson’s disease (PD) is the second fastest growing neurodegenerative disorder in the world, projected to double in numbers worldwide by 2060 and now recognised as a progressive multisystem syndrome consisting of both motor and non-motor features (Marras et al. 2018; Chaudhuri et al. 2013). In advanced PD, the syndromic nature of the condition emerges, and conventional oral management options become challenging and non-optimally effective, in part due to barriers to oral absorption of drugs (Leta et al. 2023) but also because of their associated dopaminergic pulsatile stimulation (Leta et al. 2019). This is where non-oral continuous drug delivery (CDD) methodology has shown to provide an encouraging and successful management strategy, with a wealth of data suggesting consistent motor as well as non-motor benefits (Chaudhuri et al. 2013; Leta et al. 2023; Leta et al. 2019). The data are particularly strong in relation to intrajejunal levodopa infusion (IJLI), as is evident from the Global Long-term Registry on Efficacy and Safety of LCIG (GLORIA) and Duoglobe registry datasets (Antonini et al. 2017).

Continuous drug delivery in Parkinson’s

Levodopa is the gold-standard treatment for motor features of PD but, with the progressive nature of PD, the effectiveness of levodopa diminishes over 5–10 years with development of motor fluctuations and dyskinesia (Connolly and Lang 2014).

Gastrointestinal (GI) dysfunction in PD can occur in all stages of the disease (Leta et al. 2021a; Leta et al. 2021b; Leta et al. 2023; Metta et al. 2022; Ray Chaudhuri, et al. 2016). It has been suggested that GI dysfunction is in part responsible for motor fluctuations such as delayed or no-ON, erratic absorption and consequent dyskinesias (Leta et al. 2023). There are several other pathophysiological mechanisms behind the development of both motor and non-motor fluctuations including the progressive nature of PD and the pulsatile delivery of common oral dopaminergic strategies, however, it is beyond the scope of this review to discuss these in detail (Leta et al. 2019). Focus on non-oral delivery of levodopa, to bypass the dysfunctional GI tract, is proposed and proven to be the next step in adequate control of PD symptomology (Güneş and Karavana 2022).

There are several different classes of CDD therapies currently available, as is shown in Table 1, including infusion therapies such as the Levodopa-Carbidopa intestinal gel (LCIG), Levodopa-carbidopa-entacapone intestinal gel, Apomorphine subcutaneous infusion, and the Rotigotine (RTG) transdermal patch. New strategies, such as the subcutaneous infusion of Levodopa, aiming to optimise the delivery and half-life of the pharmacological intervention, are currently under development (Ray Chaudhuri et al. 2016; Wamelen et al. 2018). This review will focus primarily on these non-oral CDD therapies given their increasing use in clinical practise globally and their effect on sleep dysfunction.

Table 1.

Summary of non-oral continuous drug delivery systems discussed

Name Formula Development phase CDD method Evidence for sleep improvement
Non-oral levodopa-based CDD
 LCIG

Levodopa

Carbidopa

 2005 EMA approved; 2015 FDA approved PEG/J Strong
 LECIG

Levodopa

Entacapone

Carbidopa

 2018 Sweden approved; 2021 other Europe PEG/J Minimal
 ND0612

Levodopa

Carbidopa

 Currently phase III (NCT04006210) SC Minimal
 ABBV-951

Foslevodopa

Foscarbidopa

 Currently phase III (NCT04380142) SC Pending
 IPO-001

Levodopa

Carbidopa

 Currently phase I (NCT03419806) SC/ IV Pending
Non-oral non-Levodopa-based CDD
 RTG patch Non-ergot dopamine agonist 2006 EMA approval; 2007 FDA approval Transdermal Moderate-strong
 APO-pump Non-ergot dopamine D2 agonist NDA approved, ongoing trials PEG/J Moderate-strong
 ND0701 Non-ergot dopamine D2 agonist Currently phase I/II Transdermal Pending
 SER-214 Non-ergot dopamine agonist Currently phase I (NCT02579473) Transdermal Pending
Open in a new tab

We classify evidence for sleep improvement based on number of evidence to that effect, adaptation of the previously suggested level of evidence ranking (Hussein et al. 2018; Teunissen et al. 2015). Minimal is classed as less than 2 articles supporting notion of sleep improvement, with more than 4 conflicting studies. Moderate is classed as 3–4 articles supporting the notion of sleep improvement, with less than 4 conflicting studies. Mod-Strong is classed as 5–6 articles supporting the notion of sleep improvement, with less than 3 conflicting studies. Strong is classed as 7 or more studies supporting the notion of sleep improvement, with less than 2 conflicting studies. Pending is classed as no evidence currently available

APO apomorphine, CDD continuous drug delivery, EMA European medicine agency, FDA Food and drug administration, IV intravenous, LCIG levodopa-carbidopa intestinal gel, LECIG levodopa-entacapone-carbidopa intestinal gel, PEG/J percutaneous endoscopic transgastric jejunostomy, RTG rotigotine, SC subcutaneous

Continuous drug delivery and sleep dysfunction

NMS burden and non-motor fluctuations have shown to increase with PD progression with advanced stages manifesting a difficult conundrum for many clinicians (Brun et al. 2014). There is a wide range of evidence (Chaudhuri et al. 2013; Chaudhuri et al. 2022a; Antonini et al. 2017; Wamelen et al. 2018) demonstrating that a variety of CDD strategies ameliorate NMS burden, with a consistent beneficial effect on sleep as reported in open label and randomised studies (Chaudhuri et al. 2013, 2022a; Antonini et al. 2017; Rosa-Grilo et al. 2017).

Sleep dysfunction is reported by 67–98% of people with Parkinson’s disease (PwP) (Medcalf 2005). Sleep dysfunction describes a spectrum of different sleep problems including disturbances of sleep, such as insomnia and rapid eye movement (REM) behaviour disorder (RBD), and disturbances of wakefulness such as excessive daytime sleepiness (EDS) (Falup-Pecurariu and Diaconu 2017). NMS burden progresses with the disease, amid sleep disturbances being, not only a common NMS in advance stages of PD but also shown to be an independent predictor of NMS burden itself (Kurlawala et al. 2021; Santos-García, et al. 2021; Dhawan et al. 2006). CDD may be beneficial in the tackling of sleep dysfunction in PD, due to the continuous delivery of dopamine throughout the night, by not only improving nocturnal motor complications, but also by improving sleep structure and reducing sleep fragmentation (Raeder et al. 2021).

Currently available levodopa-based strategies

CDD, in the form of levodopa intestinal infusion, may provide a stable plasma level of levodopa, thereby relieving both motor and non-motor fluctuations face with oral delivery alone (Antonini et al. 2017; Chaudhuri et al. 2022a; Thakkar et al. 2021). Levodopa intestinal infusion is available in current clinical practice globally, delivered as a pump-based system.

Levodopa-carbidopa intestinal gel (LCIG): a stable gel suspension, is delivered continuously via a percutaneous gastrojejunostomy and portable pump hence delivering levodopa directly to the jejunum, bypassing the GI-related absorption issues (Leta et al. 2023; Ray Chaudhuri et al. 2016; Chaudhuri et al. 2022a). LCIG has already been shown to be effective in reducing dyskinesias and other motor features in advanced PD (Standaert et al. 2017), but LCIG has robustly demonstrated to be a safe and effective option in improving sleep quality as a burdensome NMS (Honig et al. 2009). A meta-analysis study, with over 1200 advanced staged PwP, report LCIG having significantly improved NMS burden, particularly sleep outcomes, such as EDS, insomnia and nocturia, leading the authors to conclude that LCIG is an effective treatment option for advanced PwP, which can concurrently be an effective treatment for sleep burden in these cases (Chaudhuri et al. 2022a). Whilst we do not yet fully understand the pathophysiology for these improvements, Positron Emission Tomography (PET) studies have pointed to a reduction in dopaminergic D2 receptors in the hypothalamus which may provide the link between sleep disturbances in PD and dopaminergic dysfunction (Politis et al. 2008). Furthermore, LCIG was observed to have reduced both night-time and day-time sleep issues such as insomnia and EDS, respectively, as measured by PD Sleep Scale 2 (PDSS-2) and Epworth Sleepiness Scale (ESS) (Trenkwalder et al. 2011a; Kendzerska et al. 2014). Several other studies have corroborated these findings, including the GLORIA study, which found that LCIG led to persistent noteworthy reductions in NMS burden throughout its 24-month duration, with sleep/fatigue disturbances demonstrating the greatest improvement (Antonini et al. 2017). Furthermore, the currently ongoing DUOGLOBE study found significant improvements in multiple different NMS domains, including quality of sleep and daytime somnolence at a 12-month follow-up, while the results of the planned 24 and 36-month follow-up assessments may provide further understanding of this LCIG-driven changes in NMS burden over time (Standaert et al. 2021). In summary, LCIG has proven to not only be an effective therapy option for advanced PwP for motor control but there is ample evidence to show its benefit on NMS burden, specifically sleep issues.

Levodopa-carbidopa-entacapone intestinal gel (LECIG) infusion: it has been recently developed, increasing the bioavailability of levodopa further (Nyholm and Jost 2022; Senek et al. 2017, 2020; Öthman, et al. 2021). In 2018, Sweden was first to gain approval to use LECIG, which has subsequently now been approved for market in other European countries (Nyholm and Jost 2022; Senek et al. 2017). No formal study exploring NMS, let alone sleep, with LECIG application has been documented, although an ongoing international longitudinal registry of LECIG users, ELEGANCE, will ideally provide some initial information on effect of LECIG on NMS and by default, sleep (Nyholm and Jost 2022).

LCIG used in combination with opicapone: a long acting, third generation COMT inhibitor, was also demonstrated to reduce costs of this device-aided therapy (Leta et al. 2020). Open label studies have already suggested that both entacapone and tolcapone might improve sleep dysfunction and NMS burden in PwP (Muhlack et al. 2014; Park et al. 2020) and a recent retrospective open label study suggest that introduction of opicapone in real-life PwP with motor fluctuations stabilises NMS burden and aspects of sleep dysfunction after one year, while use of entacapone was associated with a worsening of the above-mentioned aspects. There are no formal studies on the use of LCIG with opicapone to address NMS or sleep issues. However, a small open label study is currently investigating the effect of oral levodopa and opicapone on sleep dysfunction (the OpiSleep study) and, if positive, it may support the use of LCIG with opicapone for night-time benefit in PD, particularly where it is not possible to use IJLI for 24 h because of various difficulties, including cost issues (Leta et al. 2020; Santos García et al. 2022; Chaudhuri et al. 2022b).

Levodopa-based strategies in development

ABBV-951: a new formulation of levodopa and carbidopa prodrugs (foslevodopa/foscarbidopa), is delivered through a continuous subcutaneous infusion delivery system connected to a pump (Rosebraugh et al. 2021; Soileau et al. 2022; Aldred et al. 2022). Phase I trials have shown promising results of lower motor fluctuations, with further promising results from recent phase III trials finding improvement in NMS, especially sleep disturbances (Soileau et al. 2022). ABBV-951 permits the delivery of varying levodopa doses, in smaller volumes than is seen in LCIG and, unlike LCIG, surgery is not required to implant the delivery device, making it an ideal non-surgically invasive CDD therapy option (Soileau et al. 2022). Ongoing longitudinal studies will work further to provide more understanding on ABBV-951 impact on NMS and sleep.

ND0612: a formulation of levodopa-carbidopa, is another continuous infusion administered via a pump which is fed through a cannula inserted into the subcutaneous layer of the skin (Giladi et al. 2021; LeWitt 2022). Although there is positive motor data from phase I and II trials, there has been little data published on its effect on NMS, specifically sleep dysfunction (Giladi et al. 2021). Despite this, the limited available data on ND0612-treated PwP have indicated improvement in sleep quality during phase I and II trials, as assessed through PDSS (Giladi et al. 2021).

IPO-001 (Infudopa): levodopa-carbidopa delivered through subcutaneous (DIX102) or intravenous (DIX101) route, is currently under phase I trials (NCT03419806) (Ray Chaudhuri et al. 2016; Larson and Simuni 2022; Bergquist et al. 2022) and there is no data on sleep or NMS.

Currently available non-levodopa based strategies

Rotigotine (RTG) transdermal patch: the first widely available transdermal therapy for PwP, is a treatment option with potential in all stages of PD (Raeder et al. 2021). RTG is a non-ergot dopamine agonist, applied using a silicon-based patch, activating dopaminergic (D1-5) receptors, alongside having high affinity for selected serotonergic (5HT1A) and adrenergic (α2) receptors (Wood et al. 2015; Jenner and Katzenschlager 2016; Chen et al. 2009). RTG patch has shown to provide stable extracellular levels, achieving continuous dopaminergic stimulation, and subsequently reducing motor fluctuations and dyskinesia (Raeder et al. 2021; Kehr et al. 2007; Zhou et al. 2013). Furthermore, RTG patch’s efficacious impact on sleep disturbances in PwP has been echoed by several studies as confirmed using sleep-specific scales (Rosa-Grilo et al. 2017; Giladi et al. 2010; Fei et al. 2019; Bhidayasiri et al. 2017; Pagonabarraga et al. 2015; Ceballos-Baumann and Häck 2011; Pierantozzi et al. 2016). The RECOVER study highlighted improvements in nocturnal sleep disturbances, such as nocturnal akinesia, RLS, immobility, cramps, tremor and nocturnal pain, alongside dopaminergic daytime NMS (Trenkwalder et al. 2011b). In placebo-controlled trials RTG patch has not replicated the significant improvement witnessed previously, however in such trials the participants were early-PD with advance PD not included, which does not reflect the burden RTG patch has shown to overcome in advance PD (Antonini et al. 2015). Finally, overnight RTG transdermal patch in combination with LCIG infusion is well tolerated in advanced PD and can further improve NMS (Lau et al. 2022).

Other application of RTG: including the combination of RTG with biodegradable bioconjugate polymers or polyoxazolines, may enhance the control of drug delivery and increase the half-life of RTG (Ray Chaudhuri et al. 2016). One such example includes SER-214 (NCT02579473), which has entered a phase 1 study in de novo PwP (Güneş and Karavana 2022).

Apomorphine subcutaneous infusion: a non-ergoline dopamine D2 agonist, is known to provide a positive impact on motor features, but also NMS of PD (Trenkwalder et al. 2015; García Ruiz et al. 2008; Martinez-Martin et al. 2011; Martinez-Martin et al. 2015; Borgemeester et al. 2016; Chaudhuri and Schapira 2009). Administration of nocturnal Apomorphine infusion has led to significant reduction in nocturnal complications (Chaudhuri and Leta 2022; Cock et al. 2022; Reuter et al. 1999). Of note, the APORMORPHEE study found a significant change in mean PDSS score, in comparison to controls, leading the authors to conclude subcutaneous night-time infusion of Apomorphine may be useful in the treatment of insomnia and other sleep disturbances in advanced PwP (Cock et al. 2022). The efficacy of nocturnal Apomorphine infusion in ameliorating RLS symptoms was also investigated, demonstrating a reduction in nocturnal discomfort, leg movement and spasms (Reuter et al. 1999). Delays in time-to-ON with levodopa are another frequent complication, known as morning akinesia, for which apomorphine has also been indicated to have a rapid improvement in time-to-ON in PwP who experience motor and non-motor fluctuations (Trenkwalder et al. 2015; Isaacson et al. 2017; Stacy and Silver 2008). The results of studies such as these suggest apomorphine can successfully overcome refractory nocturnal complications in both selected RLS patients and PwP.

Non-levodopa based strategies in development

Other applications of RTG: including the combination of RTG with biodegradable bioconjugate polymers or polyoxazolines, may enhance the control of drug delivery and increase the half-life of RTG (Ray Chaudhuri et al. 2016). One such example includes SER-214 (NCT02579473), which has entered a phase 1 study in de novo PwP (Güneş and Karavana 2022).

Apomorphine pump patch: the ND0701, is currently in Phase 1 trials (Ramot et al. 2018). Results thus far yield ND0701 as a safe and well-tolerated CDD (Ramot et al. 2018; Carbone et al. 2019), with its bioavailability matching that of standard apomorphine infusion, however, we do not currently have any data indicating ND0701s efficacy in the treatment of motor or NMS, and as a result, are not aware of its impact on sleep dysfunction.

Conclusion

CDD therapies are fundamental in providing symptomatic relief of both motor and NMS in advanced stages of PD, and in the instance of refractory symptoms. Therapies such as those outlined in this review are crucial in overcoming complications related to disease progression and the use of standard oral interventions, including GI dysfunction, motor fluctuations and dyskinesia. The developments to date in both levodopa-and non-levodopa based continuous strategies represent an exciting achievement in the effective management of PD symptoms (Fig. 1), particularly in the case of the burdensome sleep dysfunction. Alongside the successful amelioration of PD symptoms, the use of CDD provides many options for clinicians, including simplification of medication regime.

Fig. 1.

Fig. 1

Open in a new tab

Overview of non-oral continuous drug delivery strategies, currently available and under development, in Parkinson’s disease. LCIG levodopa-carbidopa intestinal gel, LCECIG levodopa-carbidopa-entacapone intestinal gel, RTG rotigotine, APO apomorphine

This review outlines the current knowledge on CDD and sleep and, in particular, of its ability to provide some relief to PwP who have advanced PD with sleep dysfunction. However, further research is needed to evaluate these CDD modalities against each other and other oral continuous therapies.

Data availability

The authors confirm that the data supporting the findings of this study are available within the article with references.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

P. Tall and M. Qamar are joint first authors.

Contributor Information

P. Tall, Email: phoebe.tall@nhs.net

M. A. Qamar, Email: mubasher.qamar@nhs.net

References

  1. Aldred J, et al. Safety and efficacy of 24-hour/day subcutaneous infusion of foslevodopa/foscarbidopa in advanced Parkinson’s disease during a phase 3 study: 6-month interim results (S16.009) Neurology. 2022;98(18 Supplement):2682. [Google Scholar]
  2. Antonini A, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms-results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22(10):1400–1407. doi: 10.1111/ene.12757. [DOI] [PubMed] [Google Scholar]
  3. Antonini A, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13–20. doi: 10.1016/j.parkreldis.2017.09.018. [DOI] [PubMed] [Google Scholar]
  4. Bergquist F, et al. Pharmacokinetics of intravenously (DIZ101), subcutaneously (DIZ102), and intestinally (LCIG) infused levodopa in advanced Parkinson disease. Neurology. 2022;99(10):e965–e976. doi: 10.1212/WNL.0000000000200804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bhidayasiri R, et al. Rotigotine for nocturnal hypokinesia in Parkinson's disease: quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor. Parkinsonism Relat Disord. 2017;44:124–128. doi: 10.1016/j.parkreldis.2017.08.010. [DOI] [PubMed] [Google Scholar]
  6. Borgemeester RWK, Drent M, van Laar T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. Parkinsonism Relat Disord. 2016;23:17–22. doi: 10.1016/j.parkreldis.2015.11.013. [DOI] [PubMed] [Google Scholar]
  7. Brun L, et al. Non-motor fluctuations in Parkinson’s disease: prevalence, characteristics and management in a large cohort of parkinsonian outpatients. Clin Neurol Neurosurg. 2014;127:93–96. doi: 10.1016/j.clineuro.2014.10.006. [DOI] [PubMed] [Google Scholar]
  8. Carbone F, et al. Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905–918. doi: 10.1007/s40263-019-00661-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ceballos-Baumann A, Häck HJ. Rotigotine transdermal patch in combination therapy for Parkinson’s disease–observations in routine clinical practice. Curr Med Res Opin. 2011;27(10):1899–1905. doi: 10.1185/03007995.2011.611630. [DOI] [PubMed] [Google Scholar]
  10. Chaudhuri KR, Leta V. Apomorphine infusion for improving sleep in Parkinson's disease. Lancet Neurol. 2022;21(5):395–398. doi: 10.1016/S1474-4422(22)00128-4. [DOI] [PubMed] [Google Scholar]
  11. Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474. doi: 10.1016/S1474-4422(09)70068-7. [DOI] [PubMed] [Google Scholar]
  12. Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm (Vienna) 2013;120(9):1305–1320. doi: 10.1007/s00702-013-0981-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Chaudhuri KR, et al. Effects of levodopa-carbidopa intestinal gel on dyskinesia and non-motor symptoms including sleep: results from a meta-analysis with 24-month follow-up. J Parkinson’s Dis. 2022;12(7):2071–2083. doi: 10.3233/JPD-223295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chaudhuri KR, et al. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone effect on motor fluctuations and pAiN) trial. BMC Neurol. 2022;22(1):88. doi: 10.1186/s12883-022-02602-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chen JJ, et al. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy. 2009;29(12):1452–1467. doi: 10.1592/phco.29.12.1452. [DOI] [PubMed] [Google Scholar]
  16. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683. doi: 10.1001/jama.2014.3654. [DOI] [PubMed] [Google Scholar]
  17. De Cock VC, et al. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol. 2022;21(5):428–437. doi: 10.1016/S1474-4422(22)00085-0. [DOI] [PubMed] [Google Scholar]
  18. Dhawan V, et al. Sleep-related problems of Parkinson’s disease. Age Ageing. 2006;35(3):220–228. doi: 10.1093/ageing/afj087. [DOI] [PubMed] [Google Scholar]
  19. Falup-Pecurariu C, Diaconu Ş. Sleep dysfunction in Parkinson’s disease. Int Rev Neurobiol. 2017;133:719–742. doi: 10.1016/bs.irn.2017.05.033. [DOI] [PubMed] [Google Scholar]
  20. Fei L, Zhou D, Ding ZT. The efficacy and safety of rotigotine transdermal patch for the treatment of sleep disorders in Parkinson's disease: a meta-analysis. Sleep Med. 2019;61:19–25. doi: 10.1016/j.sleep.2019.05.002. [DOI] [PubMed] [Google Scholar]
  21. García Ruiz PJ, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130–1136. doi: 10.1002/mds.22063. [DOI] [PubMed] [Google Scholar]
  22. Giladi N, et al. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J Neural Transm (Vienna) 2010;117(12):1395–1399. doi: 10.1007/s00702-010-0506-4. [DOI] [PubMed] [Google Scholar]
  23. Giladi N, et al. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: a randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord. 2021;91:139–145. doi: 10.1016/j.parkreldis.2021.09.024. [DOI] [PubMed] [Google Scholar]
  24. Güneş M, Karavana SY. Non-oral drug delivery in Parkinson’s disease: current applications and future. Turk J Pharm Sci. 2022;19(3):343–352. doi: 10.4274/tjps.galenos.2021.95226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Honig H, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10):1468–1474. doi: 10.1002/mds.22596. [DOI] [PubMed] [Google Scholar]
  26. Hussein AA, et al. A review of the most promising biomarkers for early diagnosis and prognosis prediction of tongue squamous cell carcinoma. Br J Cancer. 2018;119(6):724–736. doi: 10.1038/s41416-018-0233-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Isaacson S, et al. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease. Mov Disord Clin Pract. 2017;4(1):78–83. doi: 10.1002/mdc3.12350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Jenner P, Katzenschlager R. Apomorphine-pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat Disord. 2016;33:S13–S21. doi: 10.1016/j.parkreldis.2016.12.003. [DOI] [PubMed] [Google Scholar]
  29. Kehr J, et al. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm. 2007;114:1027–1031. doi: 10.1007/s00702-007-0719-3. [DOI] [PubMed] [Google Scholar]
  30. Kendzerska TB, et al. Evaluation of the measurement properties of the Epworth sleepiness scale: a systematic review. Sleep Med Rev. 2014;18(4):321–331. doi: 10.1016/j.smrv.2013.08.002. [DOI] [PubMed] [Google Scholar]
  31. Kurlawala Z, et al. Progression of nonmotor symptoms in Parkinson’s disease by sex and motor laterality. Parkinsons Dis. 2021;2021:8898887. doi: 10.1155/2021/8898887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Larson D, Simuni T. New dopaminergic therapies for PD motor complications. Neuropharmacology. 2022;204:108869. doi: 10.1016/j.neuropharm.2021.108869. [DOI] [PubMed] [Google Scholar]
  33. Lau YH, et al. Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease. J Neural Transm (Vienna) 2022;129(7):889–894. doi: 10.1007/s00702-022-02506-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Leta V, et al. Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. Expert Opin Drug Saf. 2019;18(12):1203–1218. doi: 10.1080/14740338.2019.1681966. [DOI] [PubMed] [Google Scholar]
  35. Leta V, et al. Opicapone and levodopa-carbidopa intestinal gel infusion: the way forward towards cost savings for healthcare systems? J Parkinsons Dis. 2020;10(4):1535–1539. doi: 10.3233/JPD-202022. [DOI] [PubMed] [Google Scholar]
  36. Leta V, et al. Neurogenic and anti-inflammatory effects of probiotics in Parkinson's disease: a systematic review of preclinical and clinical evidence. Brain Behav Immun. 2021;98:59–73. doi: 10.1016/j.bbi.2021.07.026. [DOI] [PubMed] [Google Scholar]
  37. Leta V, et al. Constipation is associated with development of cognitive impairment in de novo Parkinson's Disease: a longitudinal analysis of two international cohorts. J Parkinsons Dis. 2021;11(3):1209–1219. doi: 10.3233/JPD-212570. [DOI] [PubMed] [Google Scholar]
  38. Leta V, et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson’s disease. Eur J Neurol. 2023;30:1465–1480. doi: 10.1111/ene.15734. [DOI] [PubMed] [Google Scholar]
  39. Leta V et al. (2023) The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone. J Neural Transm. 10.1007/s00702-023-02603-y. Epub ahead of print. PMID: 37036498. [DOI] [PMC free article] [PubMed]
  40. LeWitt PA, et al. The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: findings from the ND0612 clinical development program. Front Neurol. 2022 doi: 10.3389/fneur.2022.1036068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Marras C, et al. Prevalence of Parkinson’s disease across North America. Npj Parkinson’s Dis. 2018;4(1):21. doi: 10.1038/s41531-018-0058-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Martinez-Martin P, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197–203. doi: 10.3233/JPD-2011-11037. [DOI] [PubMed] [Google Scholar]
  43. Martinez-Martin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30(4):510–516. doi: 10.1002/mds.26067. [DOI] [PubMed] [Google Scholar]
  44. Medcalf P. Good practice in the assessment and management of nocturnal Parkinson’s disease symptoms. Age Ageing. 2005;34(5):435–438. doi: 10.1093/ageing/afi157. [DOI] [PubMed] [Google Scholar]
  45. Metta V, et al. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. J Neurol. 2022;269(3):1154–1163. doi: 10.1007/s00415-021-10567-w. [DOI] [PubMed] [Google Scholar]
  46. Muhlack S, et al. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. J Neural Transm (Vienna) 2014;121(11):1357–1366. doi: 10.1007/s00702-014-1213-3. [DOI] [PubMed] [Google Scholar]
  47. Nyholm D, Jost WH. Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance. Ther Adv Neurol Disord. 2022;15:17562864221108018. doi: 10.1177/17562864221108018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Öthman M, et al. Initial experience of the levodopa-entacapone-carbidopa intestinal gel in clinical practice. J Pers Med. 2021;11(4):254. doi: 10.3390/jpm11040254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Pagonabarraga J, et al. Transdermal rotigotine improves sleep fragmentation in Parkinson’s disease: results of the multicenter. Prospect SLEEP-FRAM Study Parkinsons Dis. 2015;2015:131508. doi: 10.1155/2015/131508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Park KW, et al. Therapeutic effect of levodopa/carbidopa/entacapone on sleep disturbance in patients with Parkinson’s disease. J Mov Disord. 2020;13(3):205–212. doi: 10.14802/jmd.20055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Pierantozzi M, et al. Rotigotine may improve sleep architecture in Parkinson’s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140–144. doi: 10.1016/j.sleep.2016.01.016. [DOI] [PubMed] [Google Scholar]
  52. Politis M, et al. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson’s disease: an in vivo 11C-raclopride PET study. Exp Neurol. 2008;214(1):112–116. doi: 10.1016/j.expneurol.2008.07.021. [DOI] [PubMed] [Google Scholar]
  53. Raeder V, et al. Rotigotine transdermal patch for motor and non-motor Parkinson’s disease: a review of 12 Years’ clinical experience. CNS Drugs. 2021;35(2):215–231. doi: 10.1007/s40263-020-00788-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Ramot Y, et al. ND0701, a novel formulation of apomorphine for subcutaneous infusion, in comparison to a commercial apomorphine formulation: 28-day pharmacokinetic study in minipigs and a phase I study in healthy volunteers to assess the safety, tolerability. Pharmacokinet Relat Bioavailab CNS Drugs. 2018;32(5):443–454. doi: 10.1007/s40263-018-0512-x. [DOI] [PubMed] [Google Scholar]
  55. Ray Chaudhuri K, et al. Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future. Npj Parkinson's Disease. 2016;2(1):16023. doi: 10.1038/npjparkd.2016.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand. 1999;100(3):163–167. doi: 10.1111/j.1600-0404.1999.tb00732.x. [DOI] [PubMed] [Google Scholar]
  57. Rosa-Grilo M, et al. Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? NPJ Parkinsons Dis. 2017;3:28. doi: 10.1038/s41531-017-0030-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Rosebraugh M, et al. Foslevodopa/foscarbidopa: a new subcutaneous treatment for Parkinson’s disease. Ann Neurol. 2021;90(1):52–61. doi: 10.1002/ana.26073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Santos García D, et al. Opicapone improves global non-motor symptoms burden in Parkinson’s disease: an open-label prospective study. Brain Sci. 2022;12(3):383. doi: 10.3390/brainsci12030383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Santos-García D, et al. Predictors of global non-motor symptoms burden progression in Parkinson's disease. Results from the COPPADIS Cohort at 2-year follow-up. J Pers Med. 2021;11(7):626. doi: 10.3390/jpm11070626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: a randomized crossover study. Mov Disord. 2017;32(2):283–286. doi: 10.1002/mds.26855. [DOI] [PubMed] [Google Scholar]
  62. Senek M, Nyholm D, Nielsen EI. Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. Sci Rep. 2020;10(1):18057. doi: 10.1038/s41598-020-75052-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Soileau MJ, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21(12):1099–1109. doi: 10.1016/S1474-4422(22)00400-8. [DOI] [PubMed] [Google Scholar]
  64. Stacy M, Silver D. Apomorphine for the acute treatment of “off” episodes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14:85–92. doi: 10.1016/j.parkreldis.2007.07.016. [DOI] [PubMed] [Google Scholar]
  65. Standaert DG, et al. Effect of Levodopa-carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson’s disease. Mov Disord Clin Pract. 2017;4(6):829–837. doi: 10.1002/mdc3.12526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Standaert DG, et al. DUOGLOBE: one-year outcomes in a real-world study of levodopa carbidopa intestinal gel for Parkinson’s disease. Mov Disord Clin Pract. 2021;8(7):1061–1074. doi: 10.1002/mdc3.13239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Teunissen CE, et al. Body fluid biomarkers for multiple sclerosis–the long road to clinical application. Nat Rev Neurol. 2015;11(10):585–596. doi: 10.1038/nrneurol.2015.173. [DOI] [PubMed] [Google Scholar]
  68. Thakkar S, et al. 24-hour levodopa-carbidopa intestinal gel: clinical experience and practical recommendations. CNS Drugs. 2021;35(2):137–149. doi: 10.1007/s40263-020-00782-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Trenkwalder C, et al. Parkinson’s disease sleep scale—validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644–652. doi: 10.1002/mds.23476. [DOI] [PubMed] [Google Scholar]
  70. Trenkwalder C, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER) Mov Disord. 2011;26(1):90–99. doi: 10.1002/mds.23441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Trenkwalder C, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease–Clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):1023–1030. doi: 10.1016/j.parkreldis.2015.06.012. [DOI] [PubMed] [Google Scholar]
  72. van Wamelen DJ, et al. Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson’s disease. J Parkinsons Dis. 2018;8:S65–S72. doi: 10.3233/JPD-181476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Wood M, et al. Rotigotine is a potent agonist at dopamine D 1 receptors as well as at dopamine D 2 and D 3 receptors. Br J Pharmacol. 2015;172(4):1124–1135. doi: 10.1111/bph.12988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Zhou CQ, et al. Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. PLoS ONE. 2013;8(7):e69738. doi: 10.1371/journal.pone.0069738. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The authors confirm that the data supporting the findings of this study are available within the article with references.

Articles from Journal of Neural Transmission are provided here courtesy of Springer

RESOURCES